Response Evaluation Criteria in Solid Tumors 1.1: sum of longest diameters of up to five target lesions; CR, PR (≥30% decrease), SD, PD (≥20% increase or new lesion). iRECIST adjusts for pseudoprogression with immunotherapy. Does not capture metabolic or ctDNA response.
Endpoints: what this kind of term is about · animated schematic, not to scale
Category
Endpoints
technologies
3drugs
1institutions
1terms
9ideas
10A regulatory endpoint for drugs that block spread, not tumoursAI-assisted central imaging reads to cut endpoint cost and variabilityBiopsy the one lesion that is growing while the others shrinkKill combination arms early using circulating tumour DNA, before waiting for scansMake clonal clearance, not tumour shrinkage, a trial endpointPublish the disagreement between trial doctors and independent reviewers for every trialStructured, coded radiology reports for cancer response instead of free textUse a blood test at six weeks to decide whether to keep goingValidate real-world progression against central imaging reviewValidate real-world progression endpoints so pragmatic trials can use them